The size of the bioabsorbable stents market in the Middle East and Africa is expected to grow USD 527.04 billion by 2027 from USD 89.29 billion in 2022 at a CAGR of 42.63% during the forecast period.
Clinical research has demonstrated that resorbable platforms, or normally dissolving stents, offer practically identical safety and efficacy profile to medicate stents. In particular, the stent has been examined in single-arm trials and in randomized trials comparing it with a Drug-eluting stent (DES).
Imaging tests show that the absorb dissolving stent starts to break down from 6 to 12 months and is completely broken up in the middle of a few years after it is set in the supply route. Two little platinum markers stay to check the area of the first PCI. The supply route can enlarge and contract, called vasomotion, like a solid vein at two years.
Increment in cardiovascular surgeries is due to a rise in the danger of cardiovascular issues among the people suffering from obesity. As per WHO reports, cardiovascular problems are the main source of death than any other health issues, it is expected that by 2030 more than 23 million individuals may die due to Cardiovascular diseases. Thus, the aging population and an increase in cardiovascular diseases are the key driving factors for the growth of the market. Positive outcomes of surgeries with bioabsorbable stents and post-surgery reports also account for the development of the market.
However, there are many regulatory, technological, safety-efficacy and also cost-related issues that the market has to deal with before reaching its full potential.
This research report on the MEA Bioabsorbable Stents Market has been segmented and sub-segmented into the following categories.
By Absorption Rate:
By End User:
Companies dominating the MEA Bioabsorbable stents market are Elixir Medical Corporation, Arterius Limited, Amaranth Medical Inc, Abbott Laboratories, Arterial Remodeling Technologies S.A, Biotronik, Kyoto Medical Planning Co Ltd., Reva Medical Inc, Tepha.Inc, SMT, Xenogenics Corporation
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com